Isabel B.
- Country
- Spain
- Department
- Pneumonology
Research Overview
- Phase Ib Dose-Ranging Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Versus Placebo in Combination with Background Therapy in Pulmonary Arterial Hypertension
- Efficacy and Safety of Inhaled Treprostinil Liposome in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
- Phase 2 Study of REGN13335 Efficacy and Safety in Adults with Pulmonary Arterial Hypertension
Data & Insights
Has run more than one trial at 109 of 169 partner sites.
Specializations
Pulmonary Vascular Disease
The investigator specializes in pulmonary arterial hypertension (PAH) treatment and research, with extensive experience in evaluating novel therapeutic approaches through clinical studies.
- Inhaled Therapeutics Development
- Long-term Disease Management
- Advanced Stage PAH Treatment
Primary focus includes assessment of innovative inhaled medications and their effects on pulmonary vascular resistance.
Cardiovascular Therapeutics
Expertise in studying combined postcapillary and precapillary pulmonary hypertension, particularly in relation to heart failure conditions.
- Heart Failure Management
- Hemodynamic Assessment
- Exercise Capacity Evaluation
Investigates the intersection of cardiac function and pulmonary vascular disease through therapeutic interventions.
Treatment Innovation
Active involvement in evaluating combination therapy approaches and novel therapeutic agents for pulmonary vascular diseases.
- Background Therapy Optimization
- Risk Status Assessment
- Treatment Response Monitoring
Focuses on investigating emerging therapeutic options and their integration with existing treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.